NCT01006421

Brief Summary

Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available. Phototherapy is among the successful treatments but gives modest results. Some reports documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2009

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

November 1, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 2, 2009

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
Last Updated

November 5, 2009

Status Verified

November 1, 2009

First QC Date

November 1, 2009

Last Update Submit

November 4, 2009

Conditions

Vitiligo

Keywords

phototherapyGingko bilobarepigmentation

Outcome Measures

Primary Outcomes (1)

  • Repigmentation (more than 50% from baseline) as the primary outcome

    3,6 and 9 months

Secondary Outcomes (1)

  • Quality-of-life - as secondary outcome .

    3,6 and 9 months

Interventions

GINGKO BILOBADIETARY_SUPPLEMENT

MEMOREX 60 MG BID

Eligibility Criteria

Age12 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

DERMATOLOGY CLINIC

You may qualify if:

  • Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo.
  • Body surface area (BSA) involvement ≥ 3%.

You may not qualify if:

  • Unable to consent
  • Any topical, systemic or phototherapy for Vitiligo in the previous 2 months.
  • Pregnancy, breast feeding.
  • Liver or kidney disease.
  • Epilepsy
  • Bleeding disorder or anticoagulant treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King Khalid University Hospital

Riyadh, Central, Saudi Arabia

RECRUITING

MeSH Terms

Conditions

Vitiligo

Interventions

Ginkgo Extract

Condition Hierarchy (Ancestors)

HypopigmentationPigmentation DisordersSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Plant ExtractsPlant PreparationsBiological ProductsComplex Mixtures

Study Officials

  • KHALID M ALGHAMDI, MD

    KSU

    STUDY CHAIR

Central Study Contacts

KHALID M ALGHAMDI, MD

CONTACT

4690815kmgderm@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 1, 2009

First Posted

November 2, 2009

Study Start

January 1, 2009

Study Completion

January 1, 2011

Last Updated

November 5, 2009

Record last verified: 2009-11

Locations

SA(1)